Bluejay Diagnostics Inc

NASDAQ:BJDXUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a rapid, near-patient testing system for triage and monitoring of disease progression. Its product candidate, an IL-6 Test for sepsis triage, is designed to provide results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and better triage/treatment decisions. The Symphony platform is a combination of its intellectual property (IP) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges. The Symphony platform and its initial biomarker test, Symphony IL-6 test, is suited to address a subset of the global in vitro diagnostics devices market, including sepsis, cardio-metabolic diseases, cancer and other diseases that require rapid tests. Symphony targets critical care markets where physicians must quickly determine patient acuity to identify optimal treatment regimens.

Contact Information

Headquarters

360 Massachusetts Avenue, Suite 203ACTON, MA, United States 01720

Phone

978-631-0152

Fax

302-636-5454

Executives

Independent Chairman of the Board

Douglas Wurth

President, Chief Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director

Neil Dey

Chief Technology Officer

Jason Cook

Director

Svetlana Dey

Independent Director

Donald Chase